Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Up 109.7% in February

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) saw a large growth in short interest during the month of February. As of February 27th, there was short interest totaling 42,416 shares, a growth of 109.7% from the February 12th total of 20,230 shares. Based on an average trading volume of 248,360 shares, the short-interest ratio is presently 0.2 days. Approximately 6.2% of the shares of the stock are short sold. Approximately 6.2% of the shares of the stock are short sold. Based on an average trading volume of 248,360 shares, the short-interest ratio is presently 0.2 days.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, February 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ BDRX traded down $0.03 during midday trading on Friday, reaching $0.84. The company had a trading volume of 33,122 shares, compared to its average volume of 296,379. Biodexa Pharmaceuticals has a one year low of $0.81 and a one year high of $26.50. The firm’s fifty day moving average price is $1.60 and its 200-day moving average price is $4.29.

Institutional Trading of Biodexa Pharmaceuticals

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Sabby Management LLC bought a new position in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for about 0.6% of Sabby Management LLC’s holdings, making the stock its 10th biggest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 17.51% of the stock is currently owned by institutional investors.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.